Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 29 · below the Ichimoku cloud · RSI 44 · MACD above its signal · 6% above its 52-week low
None of the 29 investors followed here reported a position in 1513.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1513.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.4 | -1.2 | -5.6 | 2.7 | -6.7 | -9.1 | 8.7 | -23.4 | 14.3 | -7.4 | −26.0% | ||
| 2025 | -3.8 | -4.7 | 5.1 | -3.0 | 12.6 | 1.7 | 26.9 | -5.5 | -2.3 | -9.7 | -1.7 | -7.5 | +3.0% |
| 2024 | -1.4 | 15.1 | -2.7 | 0.9 | -1.5 | -3.0 | -6.8 | 3.5 | 19.2 | -11.5 | 1.7 | 3.8 | +14.3% |
| 2023 | 1.5 | 2.3 | 1.7 | 2.5 | -1.8 | -3.4 | -1.3 | -6.6 | 3.2 | -9.9 | 1.1 | 3.4 | −8.0% |
| 2022 | -3.2 | 6.0 | -3.8 | -5.2 | -5.6 | 7.7 | -14.0 | -4.9 | -11.4 | 4.4 | 32.4 | -3.5 | −7.9% |
| 2021 | -4.5 | -0.7 | 16.3 | 9.5 | 9.2 | -3.5 | -23.4 | -1.9 | -0.5 | -10.1 | -0.8 | 11.8 | −5.2% |
| 2020 | 11.1 | 2.4 | 3.4 | 20.7 | -9.6 | 25.5 | -7.0 | 2.2 | -4.7 | -3.4 | -10.8 | -1.5 | +23.9% |
| 2019 | 10.8 | 9.7 | -1.3 | 4.4 | -14.0 | 6.1 | -4.2 | 12.5 | -6.7 | 14.2 | 0.2 | 5.4 | +38.6% |
| 2018 | 4.7 | -9.4 | 7.9 | -10.1 | -0.6 | -13.4 | -1.7 | -14.2 | -15.1 | -15.4 | 25.1 | -20.0 | −52.1% |
| 2017 | -1.5 | 5.3 | -2.8 | 7.3 | 6.4 | 5.3 | 1.6 | -0.9 | 6.1 | 17.0 | 6.0 | 10.1 | +76.7% |
| 2016 | -6.8 | -5.9 | 4.0 | 5.9 | -1.4 | -1.8 | 10.3 | 7.0 | 16.2 | -5.3 | 10.4 | -9.1 | +21.7% |
| 2015 | -8.6 | -7.6 | 24.3 | 12.7 | 17.0 | -17.0 | -10.8 | 7.2 | 0.0 | 0.0 | -12.9 | 7.0 | +2.4% |
| 2014 | 21.6 | -17.4 | -6.9 | -0.1 | -1.8 | 11.6 | 2.4 | 9.3 | 8.0 | -9.5 | -9.8 | +1.0% |
No insider transactions reported for 1513.HK.
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment. Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.
Buy / hold / sell counts
No recent headlines.